Reteplase Injection
Last Updated: May 22, 2017
Status: Current
Reteplase Injection
-
Retavase Injection, Chiesi USA
Half Kit, one 10.4 unit single use vial (NDC 24477-0040-01)
Full Kit, two 10.4 unit single use vials (NDC 24477-0041-02)
-
- Chiesi USA acquired Cornerstone Therapeutics in March 2014.
- Cornerstone Therapeutics acquired EKR Therapeutics in June 2012. EKR Therapeutics had previously purchased Retavase from PDL BioPharma.
- Cornerstone Therapeutics was seeking FDA approval of a new supplier of the active pharmaceutical ingredient for Retevase.
-
No presentations are available.
Estimated Resupply Dates
-
Chiesi USA has Retavase on long-term back order and the company cannot estimate a release date.
| Alteplase Recombinant | Resolved |
| Argatroban Injection | Resolved |
| Lepirudin Injection | No Longer Available |
| Warfarin Sodium Tablets | Resolved |
Updated
May 22, February 7, 2017; November 8, August 10, May 13, February 29, 2016; December 16, October 28, August 12 and 11, March 9, January 7, 2015; October 17, July 31, April 16, January 14, 2014; October 15, August 5, June 13, April 12, January 16, 2013; October 19, April 5, January 4, 2012; October 12, August 2, May 3, February 28, 14 and 3, 2011; December 10, October 6, July 30, May 28, March 30, February 10, January 20 and 5, 2010; December 15, November 25, 18 and 10, October 9, 2009, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.
